Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE43.1200
- TODAY'S CHANGE (%)-0.4900 (-1.1236%)
- Bid / Lots37.0000/ 1
- Ask / Lots43.1200/ 1
- Open / Previous Close43.8100 / 43.6100
- Day Range
- 52 Week Range
- Volume1,099,299
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 2625 | 43.788 |
| 09:34 ET | 100 | 43.615 |
| 09:36 ET | 100 | 44.07 |
| 09:38 ET | 200 | 44.04 |
| 09:39 ET | 236 | 44.085 |
| 09:43 ET | 200 | 43.855 |
| 09:52 ET | 100 | 43.67 |
| 09:54 ET | 300 | 43.68 |
| 09:56 ET | 100 | 43.53 |
| 10:03 ET | 927 | 43.705 |
| 10:08 ET | 200 | 43.96 |
| 10:12 ET | 200 | 43.95 |
| 10:14 ET | 1806 | 44.09 |
| 10:17 ET | 270 | 44.22 |
| 10:21 ET | 1154 | 43.89 |
| 10:24 ET | 400 | 43.96 |
| 10:26 ET | 300 | 43.94 |
| 10:28 ET | 300 | 43.92 |
| 10:30 ET | 100 | 43.87 |
| 10:32 ET | 200 | 43.82 |
| 10:33 ET | 2155 | 43.95 |
| 10:35 ET | 700 | 43.86 |
| 10:37 ET | 500 | 43.98 |
| 10:39 ET | 700 | 43.91 |
| 10:46 ET | 100 | 43.9 |
| 10:50 ET | 700 | 44 |
| 10:51 ET | 200 | 43.88 |
| 10:55 ET | 100 | 43.865 |
| 11:04 ET | 589 | 43.71 |
| 11:06 ET | 100 | 43.75 |
| 11:09 ET | 100 | 43.71 |
| 11:11 ET | 597 | 43.685 |
| 11:13 ET | 430 | 43.38 |
| 11:15 ET | 400 | 43.4 |
| 11:18 ET | 100 | 43.405 |
| 11:22 ET | 200 | 43.31 |
| 11:24 ET | 600 | 43.48 |
| 11:26 ET | 400 | 43.44 |
| 11:27 ET | 200 | 43.38 |
| 11:29 ET | 105 | 43.31 |
| 11:31 ET | 200 | 43.32 |
| 11:33 ET | 200 | 43.32 |
| 11:36 ET | 401 | 43.53 |
| 11:38 ET | 100 | 43.505 |
| 11:40 ET | 500 | 43.46 |
| 11:42 ET | 350 | 43.39 |
| 11:44 ET | 200 | 43.37 |
| 11:45 ET | 300 | 43.32 |
| 11:47 ET | 429 | 43.38 |
| 11:49 ET | 550 | 43.3 |
| 11:51 ET | 323 | 43.25 |
| 11:54 ET | 1450 | 43.405 |
| 11:56 ET | 400 | 43.445 |
| 11:58 ET | 100 | 43.48 |
| 12:02 ET | 100 | 43.59 |
| 12:09 ET | 500 | 43.5 |
| 12:12 ET | 902 | 43.445 |
| 12:14 ET | 300 | 43.4537 |
| 12:18 ET | 200 | 43.39 |
| 12:25 ET | 234 | 43.5 |
| 12:34 ET | 400 | 43.55 |
| 12:36 ET | 1000 | 43.54 |
| 12:38 ET | 100 | 43.5512 |
| 12:39 ET | 100 | 43.49 |
| 12:41 ET | 100 | 43.465 |
| 12:43 ET | 300 | 43.57 |
| 12:45 ET | 400 | 43.49 |
| 12:48 ET | 300 | 43.535 |
| 12:50 ET | 107 | 43.49 |
| 12:52 ET | 200 | 43.47 |
| 12:57 ET | 816 | 43.62 |
| 12:59 ET | 200 | 43.61 |
| 01:01 ET | 498 | 43.61 |
| 01:06 ET | 100 | 43.59 |
| 01:08 ET | 100 | 43.64 |
| 01:12 ET | 719 | 43.57 |
| 01:14 ET | 534 | 43.5 |
| 01:15 ET | 712 | 43.51 |
| 01:17 ET | 300 | 43.44 |
| 01:19 ET | 100 | 43.4 |
| 01:21 ET | 545 | 43.4 |
| 01:24 ET | 556 | 43.43 |
| 01:26 ET | 400 | 43.39 |
| 01:28 ET | 501 | 43.34 |
| 01:30 ET | 1330 | 43.28 |
| 01:32 ET | 1059 | 43.26 |
| 01:33 ET | 300 | 43.25 |
| 01:35 ET | 522 | 43.22 |
| 01:37 ET | 200 | 43.19 |
| 01:39 ET | 300 | 43.13 |
| 01:42 ET | 100 | 43.155 |
| 01:46 ET | 3149 | 43.195 |
| 01:48 ET | 500 | 43.16 |
| 01:50 ET | 100 | 43.15 |
| 01:51 ET | 1937 | 43.03 |
| 01:53 ET | 200 | 42.99 |
| 01:55 ET | 1306 | 42.98 |
| 01:57 ET | 300 | 43 |
| 02:00 ET | 2734 | 43.06 |
| 02:02 ET | 700 | 43.07 |
| 02:04 ET | 200 | 43.005 |
| 02:06 ET | 1225 | 43.105 |
| 02:08 ET | 200 | 43.06 |
| 02:09 ET | 536 | 43.135 |
| 02:11 ET | 1153 | 43.2 |
| 02:13 ET | 1544 | 43.25 |
| 02:15 ET | 1221 | 43.29 |
| 02:18 ET | 200 | 43.32 |
| 02:20 ET | 121 | 43.3 |
| 02:22 ET | 4326 | 43.24 |
| 02:24 ET | 320 | 43.22 |
| 02:26 ET | 100 | 43.225 |
| 02:27 ET | 485 | 43.235 |
| 02:29 ET | 200 | 43.16 |
| 02:31 ET | 400 | 43.135 |
| 02:33 ET | 2650 | 43.206 |
| 02:40 ET | 604 | 43.15 |
| 02:42 ET | 100 | 43.18 |
| 02:44 ET | 7327 | 43.19 |
| 02:47 ET | 100 | 43.225 |
| 02:51 ET | 300 | 43.19 |
| 02:54 ET | 300 | 43.19 |
| 02:56 ET | 100 | 43.2 |
| 02:58 ET | 200 | 43.23 |
| 03:00 ET | 100 | 43.22 |
| 03:02 ET | 1529 | 43.21 |
| 03:03 ET | 603 | 43.15 |
| 03:05 ET | 3602 | 43.19 |
| 03:07 ET | 1124 | 43.22 |
| 03:09 ET | 1865 | 43.38 |
| 03:12 ET | 10250 | 43.335 |
| 03:14 ET | 1082 | 43.36 |
| 03:16 ET | 2093 | 43.32 |
| 03:18 ET | 1095 | 43.29 |
| 03:20 ET | 1907 | 43.33 |
| 03:21 ET | 1297 | 43.345 |
| 03:23 ET | 1389 | 43.415 |
| 03:25 ET | 1904 | 43.49 |
| 03:27 ET | 2347 | 43.51 |
| 03:30 ET | 2369 | 43.51 |
| 03:32 ET | 2550 | 43.54 |
| 03:34 ET | 1600 | 43.515 |
| 03:36 ET | 3154 | 43.56 |
| 03:38 ET | 1704 | 43.575 |
| 03:39 ET | 800 | 43.57 |
| 03:41 ET | 3567 | 43.615 |
| 03:43 ET | 2674 | 43.63 |
| 03:45 ET | 4154 | 43.59 |
| 03:48 ET | 2040 | 43.55 |
| 03:50 ET | 5946 | 43.49 |
| 03:52 ET | 5611 | 43.58 |
| 03:54 ET | 8070 | 43.45 |
| 03:56 ET | 11795 | 43.7 |
| 03:57 ET | 56099 | 43.12 |
| 03:59 ET | 41550 | 43.12 |
Jun 15, 2024
Agios Presents Positive Results from Phase 3 -2-, from 8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
Jun 13, 2024
DJ Agios Pharmaceuticals Price Target Announced at $46.00/Share by JP Morgan, from 5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 6, 2024
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET, from 9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 4, 2024
DJ Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
11:26AM ET on Tuesday Jun 04, 2024 by Dow JonesDJ Agios Pharmaceuticals Is Maintained at Outperform by RBC Capital, from 9:41AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:41AM ET on Tuesday Jun 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.4B | -6.8x | --- |
Celldex Therapeutics Inc | 2.4B | -13.0x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.6x | --- |
Geron Corp | 2.5B | -12.2x | --- |
Apogee Therapeutics Inc | 2.3B | -19.3x | --- |
Intellia Therapeutics Inc | 2.2B | -4.2x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 83.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
